
Cybersecurity requirements, which are being debated in Brussels these months, could herald markedly higher encryption and cybersecurity expenses for many firms, including those in the life sciences industry, as evident in the European Commission's impact assessment of its revised cybersecurity directive proposal, the NIS2.
Were it only up to the Commission and members of the European Parliament, more companies – including, for instance, drugmakers – would face new rules pertaining to encryption and the reporting of cyberattacks, and more.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Fruergaard leveraging experience from Danish partnerships in key roles in Brussels
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.